13F Holdings
中文EN

TNXP Tonix Pharmaceuticals Holding Corp.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1430306 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY318.0%
TTM net income YoY-82.4%
TTM EPS YoY-104.4%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin89.3%
Operating margin-436.3%
Net margin-420.4%
FCF margin-395.0%
EBITDA margin-431.0%

Returns

ROE-84.1%
ROA-73.1%
ROIC (approx.)-387.9%
Asset turnover0.17x

Leverage & solvency

Liabilities / assets17.7%
Debt / equity0.00x
Current ratio4.57x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.91x
Accruals ratio-6.3%
Payout ratio—
Capex / revenue11.0%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$13.11M$10.09M$7.77M——
Cost of revenue$6.64M$7.76M$4.74M——
Gross profit$6.47M$2.33M$3.03M——
R&D expense$44.49M$39.97M$86.66M$81.88M$68.84M
SG&A expense$87.68M$40.10M$34.75M$30.21M$23.47M
Operating income-$125.70M-$136.70M-$118.38M-$112.09M-$92.31M
Interest expense$89,000$1.23M———
Pretax income-$34.03M-$80.59M-$18.45M-$21.74M-$18.60M
Net income-$124.02M-$130.04M-$116.66M-$110.22M-$92.29M
EBITDA-$123.78M-$133.28M-$114.09M-$110.84M-$92.26M
EPS (basic)-14.57-176.60-14,720.25-20.01-8.10
EPS (diluted)-14.57-176.60-14,720.25-20.01-8.10
Weighted avg. shares (diluted)8.51M736,3397,9255.84M11.39M
Balance sheet
Cash & equivalents$207.64M$99.68M$25.85M$120.47M$178.90M
Receivables$6.27M$3.68M———
Inventory—$8.41M$13.64M——
Current assets$228.88M$119.00M$47.77M$130.78M$189.05M
PP&E, net$44.46M$42.25M$94.03M$93.81M$50.56M
Goodwill——$965,000——
Intangibles$120,000$120,000$9.74M$120,000$120,000
Total assets$277.17M$162.89M$154.46M$225.69M$240.90M
Current liabilities$30.84M$18.31M$18.88M$18.18M$21.72M
Short-term debt—$2.82M$2.35M——
Long-term debt—$4.67M$6.56M——
Total debt—$7.49M$8.91M——
Total liabilities$32.02M$23.33M$48.93M$18.51M$22.18M
Shareholders' equity$245.15M$139.56M$105.53M$207.18M$218.72M
Net debt—-$92.19M-$16.94M——
Shares outstanding12.79M4.39M20,92612.37M15.64M
Cash flow statement
Operating cash flow-$99.84M-$60.92M-$102.00M-$98.05M-$75.56M
Capital expenditure$3.37M$120,000$7.89M$48.15M$35.31M
Free cash flow-$103.21M-$61.05M-$109.90M-$146.20M-$110.86M
Investing cash flow-$4.53M-$120,000-$29.07M-$48.15M-$35.31M
Financing cash flow$214.53M$134.87M$36.52M$87.84M$212.49M
Depreciation & amortization$1.93M$3.42M$4.29M$1.25M$50,000
Stock-based compensation$6.02M$4.78M$9.28M$10.91M$7.90M
Share buybacks$13.76M—$13.96M——

Free plan shows the latest 5 periods; Pro shows all 18 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.